[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
OBJECTIVE
To evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes.


METHODS
A total of 219 treatment-naïve patients with type 2 diabetes from 6 centers were enrolled in this study and blindly divided into nateglinide group (n = 105) and repaglinide group (n = 114). In all patients, the disease was confirmed for at least three months. The whole observation lasted for 12 weeks. The efficacy indicators measured include glycohemoglobin A1c (HbA1c), fasting blood glucose, and 2 hours postprandial blood glucose, and the safety parameters measured included renal and hepatic function, serum lipids, and blood and urea profiles.


RESULTS
Similar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbA1 c were found in both nateglinide group and repaglinide group without significant differences. No severe adverse events were noted. The hypoglycemia event reports were not significantly different between these two groups.


CONCLUSIONS
Nateglinide is an effective and safe drug in treating type 2 diabetes.
Li
Yu-Xiu
YX
Department of Endocrinology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. liyuxiu@hotmail.com
Ding
Guo-Xian
GX
Li
Qi-Fu
QF
Chen
Li
L
Hu
Guo-Liang
GL
Ji
Qiu-He
QH
Wang
Shou-Jun
SJ
Guo
Yan
Y
Luo
Rong
R
Hou
Wei-Kai
WK
Wang
Pu-Neng
PN
Zhang
Nan-Yan
NY
Zhang
Ya-Ping
YP
Wang
Heng
H
D001786:Blood Glucose / Q000187:drug effects; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine